Open Access

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study

  • Authors:
    • Chia‑Hsiang Hu
    • Chun‑Nan Yeh
    • Jen‑Shi Chen
    • Chun‑Yi Tsai
    • Shang‑Yu Wang
    • Chi‑Tung Cheng
    • Ta‑Sen Yeh
  • View Affiliations

  • Published online on: June 19, 2020     https://doi.org/10.3892/ol.2020.11756
  • Pages: 2131-2142
  • Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to conduct a prognosis analysis of Taiwanese patients with metastatic gastrointestinal stromal tumors (GISTs), who are resistant to or were unable to tolerate imatinib or sunitinib, and were subsequently treated with regorafenib. The study considered the survival, potential prognostic factors and safety of these Taiwanese patients. A total of 28 patients with pre‑treated metastatic GIST, receiving regorafenib treatment, were analyzed between April 2014 and December 2017. Data were collected prospectively, and patients were followed up for a median of 14.8 months. It was reported that 50% (10/20) of male patients and 50% (4/8) of female patients demonstrated response and clinical benefit to regorafenib. The median progression‑free survival (PFS) and overall survival (OS) time in all patients receiving regorafenib were 4.4 and 29.3 months, respectively. Good performance status and disease control mediated by regorafenib were independently associated with a more favorable PFS time. Good performance status, higher pre‑treated albumin level, lower neutrophil:lymphocyte ratio (NLR) and lower platelet:lymphocyte ratio (PLR) were independent favorable predictors of OS time. Overall, poor performance status and poor disease control predicted a less favorable PFS time in Taiwanese patients with GISTs, who were pre‑treated with regorafenib. Meanwhile poor performance status, high NLR, PLR and low albumin level predicted a less favorable OS time.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hu CH, Yeh CN, Chen JS, Tsai CY, Wang SY, Cheng CT and Yeh TS: Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study. Oncol Lett 20: 2131-2142, 2020
APA
Hu, C., Yeh, C., Chen, J., Tsai, C., Wang, S., Cheng, C., & Yeh, T. (2020). Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study. Oncology Letters, 20, 2131-2142. https://doi.org/10.3892/ol.2020.11756
MLA
Hu, C., Yeh, C., Chen, J., Tsai, C., Wang, S., Cheng, C., Yeh, T."Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study". Oncology Letters 20.3 (2020): 2131-2142.
Chicago
Hu, C., Yeh, C., Chen, J., Tsai, C., Wang, S., Cheng, C., Yeh, T."Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study". Oncology Letters 20, no. 3 (2020): 2131-2142. https://doi.org/10.3892/ol.2020.11756